keyword
MENU ▼
Read by QxMD icon Read
search

small call lung cancer

keyword
https://www.readbyqxmd.com/read/29103030/mir-30a-5p-together-with-mir-210-3p-as-a-promising-biomarker-for-non-small-cell-lung-cancer-a-preliminary-study
#1
Weronika Świtlik, Michał Seweryn Karbownik, Michał Suwalski, Józef Kozak, Janusz Szemraj
BACKGROUND: Although an immense effort has been made to develop novel diagnostic methods and treatment strategies for non-small cell lung cancer (NSCLC), the survival rate of this disease has remained virtually unchanged. Small non-coding RNAs called microRNAs (miRNAs) have appeared to be very promising biomarkers of cancer including NSCLC. OBJECTIVE: We investigated the expression level of six miRNAs, and subsequently we evaluated their diagnostic ability and their clinical significance...
October 27, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29100447/can-peripheral-blood-be-used-as-surrogate-in-detecting-epidermal-growth-factor-receptor-mutation-status-in-advanced-non-small-cell-lung-cancer-patients-a-meta-analysis
#2
Xiaowei Mao, Yujun Zhang, Fangfang Xie, Xiaoxuan Zheng, Jiayuan Sun
Background: Apply peripheral blood as a surrogate for detecting epidermal growth factor receptor mutation status in tumor, also called liquid biopsy, has been reported to be a feasible method in patients with advanced non-small lung cancer. But the diagnostic yield varies in different studies. Methods: A meta-analysis was carried out to evaluate the sensitivity and specificity of peripheral blood in detection epidermal growth factor receptor mutation status in advanced non-small lung cancer patients...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29084031/companion-and-complementary-diagnostics-focus-on-pd-l1-expression-assays-for-pd-1-pd-l1-checkpoint-inhibitors-in-nsclc
#3
Maria Hersom, Jan Trøst Jørgensen
Over the last couple of decades, molecular diagnostics have played an increasing role in drug development. Especially within oncology, more and more drugs are being developed together with a predictive biomarker assay using the drug-diagnostic co-development model. Not only do these assays support the development process but also the use of the drugs after regulatory approval as an important treatment decision tool. When these predictive biomarker assays are linked to a specific drug, they are called companion diagnostics...
October 27, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29078211/-personalized-therapy-of-lung-cancer-current-standard-and-future-challenges
#4
Richard Riedel, Jürgen Wolf
So called "personalized therapy" has revolutionized the care of non-small cell lung cancer (NSCLC). The discovery of more and more driver mutations in NSCLC has led to a molecular defined sub classification of lung cancer patients. For four driver mutations (EGFR(mut), ALK(transl), ROS1(transl), BRAF-V600(mut)) firstline approved drugs are available and became the treatment of choice. Further drugs are in clinical development or can be used as off-label treatment. The emergence of resistance under targeted therapy, the development of new drugs for further driver mutations and the broad implementation of molecular diagnostics for all lung cancer patients are future challenges...
November 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29069863/combination-of-platelet-count-and-lymphocyte-to-monocyte-ratio-is-a-prognostic-factor-in-patients-undergoing-surgery-for-non-small-cell-lung-cancer
#5
Wei Liu, Minwen Ha, Nanchang Yin
The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29066671/-landscape-of-lung-cancer-with-oligometastasis
#6
Yasushi Goto, Jun Sato
Lung cancer with a few to several metastases is so-called oligometastatic disease. Patient with recurrence only to limited site is also known as oligo-recurrence, and may be included as oligometastatic disease. From biological aspect, any existence of metastases is a sign of systemic disease. Due to the reports of long survival with only local treatment and without systemic disease in oligometastatic lung cancer, word of oligometastasis is used with fascinating expectation of cure to advanced lung cancer. Most of the previous reports are retrospective and no comprehensive data exists for selecting patient for local treatment to oligometastasis...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29057240/emerging-uses-of-circulating-tumor-dna-in-advanced-stage-non-small-cell-lung-cancer
#7
REVIEW
Melina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, Tracey L Evans, Erica Carpenter, Roger B Cohen, Corey J Langer, Joshua Bauml
Targeted therapies have dramatically changed the treatment paradigm for a select group of patients with non-small cell lung cancer (NSCLC) whose tumors harbor targetable genetic aberrations. Patients with such genetic changes enjoy excellent responses to tyrosine kinase inhibitors (TKIs), but resistance is nearly inevitable. Resistance to first line TKIs is heterogeneous and multifactorial-multiple resistance mechanisms have been reported, and different metastatic foci in the same patient may have distinct resistance mechanisms...
September 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29024572/radiological-manifestations-of-immune-related-adverse-effects-observed-in-patients-with-melanoma-undergoing-immunotherapy
#8
Parveen Sidhu, Alexander M Menzies, Georgina Long, Matteo Carlino, Shirleen Lorens, Rony Kapoor
Immunotherapy drugs work by stimulating the patient's own immune system to recognize and destroy cancer cells. This subclass of drugs is increasingly administered to patients with advanced melanoma. They are also commonly incorporated into other cancer therapies such as non-small cell lung cancer, renal cancer, head and neck cancers and Hodgkin lymphoma. The most commonly administered immunotherapeutic agents in the treatment of melanoma include programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and a subclass of cytokines...
October 11, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28993508/personalized-sirna-nanoparticle-systemic-therapy-using-metastatic-lymph-node-specimens-obtained-with-ebus-tbna-in-lung-cancer
#9
Tatsuya Kato, Daiyoon Lee, Huang Huang, William Cruz-Munoz, Hideki Ujiie, Kosuke Fujino, Hironobu Wada, Priya Patel, Hsin-Pei Hu, Kentaro Hirohashi, Takahiro Nakajima, Masaaki Sato, Mitsuhito Kaji, Kichizo Kaga, Yoshiro Matsui, Juan Chen, Gang Zheng, Kazuhiro Yasufuku
Inhibiting specific gene expression with short interfering RNA (siRNA) provides a new therapeutic strategy to tackle many diseases at the molecular level. Recent strategies called high-density lipoprotein (HDL)-mimicking peptide-phospholipid nanoscaffold (HPPS) nanoparticles have been used to induce siRNAs-targeted delivery to scavenger receptor class B type I receptor (SCARB1) expressing cancer cells with high efficiency. Here, eight ideal therapeutic target genes were identified for advanced lung cancer throughout the screenings using endobronchial ultrasonography-guided transbronchial needle aspiration (EBUS-TBNA) and the establishment of a personalized siRNA-nanoparticle therapy...
October 9, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28975020/a-case-of-neuroendocrine-carcinoma-developing-from-the-broad-ligament-of-the-uterus
#10
Yui Itonaga, Masakazu Nishida, Harunobu Matsumoto, Kaei Nasu, Hisashi Narahara
Neuroendocrine carcinoma (NEC), also called small cell carcinoma or large cell carcinoma, is a rare and aggressive tumor that develops mainly in the lung and intestine. More rarely, NEC develops in gynecologic organs, with poor prognoses. We experienced a case of NEC in the broad ligament of the uterus. The patient was a 74-year-old woman with symptoms of abdominal distension and constipation. Ultrasound sonography detected an abdominal tumor larger than 10 cm. She was then admitted to our hospital. She underwent surgery under the diagnosis of ovarian cancer, but the bilateral ovaries and uterus were normal in appearance, and a tumor was developing instead from the broad ligament of the uterus...
July 3, 2017: Rare Tumors
https://www.readbyqxmd.com/read/28953246/air-quality-effects-on-human-health-and-approaches-for-its-assessment-through-microfluidic-chips
#11
REVIEW
Frank Schulze, Xinghua Gao, Darius Virzonis, Samar Damiati, Marlon R Schneider, Rimantas Kodzius
Air quality depends on the various gases and particles present in it. Both natural phenomena and human activities affect the cleanliness of air. In the last decade, many countries experienced an unprecedented industrial growth, resulting in changing air quality values, and correspondingly, affecting our life quality. Air quality can be accessed by employing microchips that qualitatively and quantitatively determine the present gases and dust particles. The so-called particular matter 2.5 (PM2.5) values are of high importance, as such small particles can penetrate the human lung barrier and enter the blood system...
September 27, 2017: Genes
https://www.readbyqxmd.com/read/28891712/molecular-and-clinical-features-of-second-generation-anaplastic-lymphoma-kinase-inhibitors-ceritinib
#12
Tommaso De Pas, Laura Pala, Chiara Catania, Fabio Conforti
The discovery of ALK rearrangement in non-small-cell lung cancer (NSCLC) triggered rapid clinical development of a family of specific drugs targeting this alteration, called ALK inhibitors. Despite high rate of responses, the vast majority of patients treated with first-generation ALK inhibitor crizotinib will ultimately develop disease progression. The second-generation ALK inhibitor, ceritinib, is an oral, small-molecule that inhibits the ALK kinase activity with a potency 20-fold greater than crizotinib, being able to tackle some of the principal mechanisms of resistance to crizotinib...
September 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/28883747/proton-beam-therapy-in-non-small-cell-lung-cancer-state-of-the-art
#13
REVIEW
Hideyuki Harada, Shigeyuki Murayama
This review summarizes the past and present status of proton beam therapy (PBT) for lung cancer. PBT has a unique characteristic called the Bragg peak that enables a reduction in the dose of normal tissue around the tumor, but is sensitive to the uncertainties of density changes. The heterogeneity in electron density for thoracic lesions, such as those in the lung and mediastinum, and tumor movement according to respiration necessitates respiratory management for PBT to be applied in lung cancer patients. There are two types of PBT - a passively scattered approach and a scanning approach...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28862766/genomic-profiles-of-lung-cancer-associated-with-idiopathic-pulmonary-fibrosis
#14
Ji An Hwang, Deokhoon Kim, Sung-Min Chun, SooHyun Bae, Joon Seon Song, Mi Young Kim, Hyun Jung Koo, Jin Woo Song, Woo Sung Kim, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi, Se Jin Jang
Little is known on the pathogenesis or molecular profiles of idiopathic pulmonary fibrosis-associated lung cancer (IPF-LC). This study was performed to investigate the genomic profiles of IPF-LC and to explore the possibility of defining potential therapeutic targets in IPF-LC. We assessed genomic profiles of IPF-LC using targeted exome sequencing (OncoPanel version 2) in 35 matched tumor/normal pairs surgically resected between 2004 and 2014. Germline and somatic variant calling was performed using GATK HaplotypeCaller and MuTect with GATK SomaticIndelocator, respectively...
September 1, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28860940/limbic-encephalitis-a%C3%A2-report-of-four-cases
#15
Żanna Pastuszak, Adam Stępień, Kazimierz Tomczykiewicz, Renata Piusińska-Macoch, Joanna Kordowska, Dariusz Galbarczyk, Jarosław Świstak
Usually limbic encephalitis (LE) is a paraneoplastic neurologic syndrome. LE symptoms can precede cancer even by a few years. Almost 50% of LE cases are connected with small cell lung carcinoma. Testis and breast cancers, granulomatous disease, thymoma, and teratomas are also often connected with LE. Other cases have infectious and autoimmunological aetiology. In LE limbic system dysfunction is observed, and it is accompanied by cerebellum and brain stem abnormalities as well as polyneuropathy. Paraneoplastic limbic encephalitis is sometimes a part of larger syndrome in which brain stem and spinal cord are involved in an inflammatory process called paraneoplastic encephalomyelitis...
2017: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/28859986/kribb11-accelerates-mcl-1-degradation-through-an-hsf1-independent-mule-dependent-pathway-in-a549-non-small-cell-lung-cancer-cells
#16
Min-Jung Kang, Hye Hyeon Yun, Jeong-Hwa Lee
The Bcl-2 family protein, Mcl-1 is known to have anti-apoptotic functions, and depletion of Mcl-1 by cellular stresses favors the apoptotic process. Moreover, Mcl-1 levels are frequently increased in various cancer cells, including non-small cell lung cancer (NSCLC), and is implicated in resistance to conventional chemotherapy and in cancer metastasis. In this study, we demonstrated that KRIBB11 accelerates the proteasomal degradation of Mcl-1 in the NSCLC cell line, A549. While KRIBB11 is an inhibitor of HSF1, we found that KRIBB11 induced Mcl-1 degradation in an HSF1-independent manner...
October 21, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28825843/immunopet-imaging-of-cd146-in-murine-models-of-intrapulmonary-metastasis-of-non-small-cell-lung-cancer
#17
Christopher G England, Dawei Jiang, Reinier Hernandez, Haiyan Sun, Hector F Valdovinos, Emily B Ehlerding, Jonathan W Engle, Yunan Yang, Peng Huang, Weibo Cai
CD146 has been identified as an excellent biomarker for lung cancer as its overexpression in solid tumors has been linked to disease progression, invasion, and metastasis. Previously, our group described a positive correlation between (64)Cu-labeled YY146 uptake and increased expression of CD146 in six human lung cancer cell lines using subcutaneous tumor models. In this study, we investigate a monoclonal antibody called YY146 for immunoPET imaging of CD146 in two intrapulmonary metastasis models of non-small cell lung cancer (NSCLC)...
October 2, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28820254/blockade-of-asparagine-endopeptidase-inhibits-cancer-metastasis
#18
Qi Qi, Obiamaka Obianyo, Yuhong Du, Haian Fu, Shiyong Li, Keqiang Ye
Asparagine endopeptidase (AEP), also called legumain, is highly expressed in various solid tumors, promoting cancer cell invasion, migration, and metastasis. It has been proposed to be a prognostic marker and therapeutic target for cancer treatment. However, an effective nonpeptide, small-molecule inhibitor against this protease has not yet been identified. Here we show that a family of xanthine derivatives selectively inhibit AEP and suppress matrix metalloproteinase (MMP) cleavage, leading to the inhibition of cancer metastasis...
September 14, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28797700/4dct-imaging-to-assess-radiomics-feature-stability-an-investigation-for-thoracic-cancers
#19
Ruben T H M Larue, Lien Van De Voorde, Janna E van Timmeren, Ralph T H Leijenaar, Maaike Berbée, Meindert N Sosef, Wendy M J Schreurs, Wouter van Elmpt, Philippe Lambin
BACKGROUND AND PURPOSE: Quantitative tissue characteristics derived from medical images, also called radiomics, contain valuable prognostic information in several tumour-sites. The large number of features available increases the risk of overfitting. Typically test-retest CT-scans are used to reduce dimensionality and select robust features. However, these scans are not always available. We propose to use different phases of respiratory-correlated 4D CT-scans (4DCT) as alternative. MATERIALS AND METHODS: In test-retest CT-scans of 26 non-small cell lung cancer (NSCLC) patients and 4DCT-scans (8 breathing phases) of 20 NSCLC and 20 oesophageal cancer patients, 1045 radiomics features of the primary tumours were calculated...
August 7, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28790336/identifying-the-mirna-signature-associated-with-survival-time-in-patients-with-lung-adenocarcinoma-using-mirna-expression-profiles
#20
Srinivasulu Yerukala Sathipati, Shinn-Ying Ho
Lung adenocarcinoma is a multifactorial disease. MicroRNA (miRNA) expression profiles are extensively used for discovering potential theranostic biomarkers of lung cancer. This work proposes an optimized support vector regression (SVR) method called SVR-LUAD to simultaneously identify a set of miRNAs referred to the miRNA signature for estimating the survival time of lung adenocarcinoma patients using their miRNA expression profiles. SVR-LUAD uses an inheritable bi-objective combinatorial genetic algorithm to identify a small set of informative miRNAs cooperating with SVR by maximizing estimation accuracy...
August 8, 2017: Scientific Reports
keyword
keyword
106365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"